Andrew J. Souers

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Andrew J. Souers, Joel D. Leverson, Erwin R. Boghaert et al. · Nature Medicine · 2013 · 3K citations

Medicine, Oncology, Pharmacology +10

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy

Joel D. Leverson, Darren C. Phillips, Michael J. Mitten et al. · Science Translational Medicine · 2015 · 541 citations · Full text

Medicine, Oncology, Pharmacology +14

Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)

H Zhang, J Chen, Sajid Khan Tahir et al. · Cell Death and Disease · 2015 · 429 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16

Discovery of a Potent and Selective BCL-X _L Inhibitor with <i>in Vivo</i> Activity

Zhi‐Fu Tao, Lisa Hasvold, Le Wang et al. · ACS Medicinal Chemistry Letters · 2014 · 331 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +10

Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models

Elizabeth A. Punnoose, Joel D. Leverson, Franklin Peale et al. · Molecular Cancer Therapeutics · 2016 · 309 citations

Medicine, Pharmacology, Chemotherapy +11